预约演示
更新于：2025-05-16
Atomoxetine Hydrochloride
盐酸托莫西汀
更新于：2025-05-16
概要
基本信息
简介托莫西汀是一种由 Eli Lilly 研制的小分子药物，于 2002 年获得了首个医学批准。该药物的作用是抑制大脑中的去甲肾上腺素再摄取，诱导突触间隙中去甲肾上腺素水平升高。该药物的主要适应症是注意力缺陷多动障碍 (ADHD)，这是一种以注意力不集中、冲动和多动为特征的疾病。托莫西汀被认为可以通过增强患有多动症的人的注意力和注意力来发挥作用。综合考虑，托莫西汀复杂的作用机制和临床适应症使其成为 ADHD 患者的一种有价值的治疗选择。 |
药物类型 小分子化药 |
别名 (-)-Tomoxetine、Atomoxetine、Atomoxetine hydrochloride (JAN/USP) + [9] |
靶点 |
作用方式 抑制剂 |
作用机制 NET抑制剂(去甲肾上腺素转运蛋白抑制剂) |
治疗领域 |
在研适应症 |
非在研适应症 |
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2002-11-26), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C17H22ClNO |
InChIKeyLUCXVPAZUDVVBT-UNTBIKODSA-N |
CAS号82248-59-7 |
关联
231
项与 盐酸托莫西汀 相关的临床试验NCT06573970
Atomoxetine Effect on Attention, Executive Function, and Quality of Life in Veterans With Posttraumatic Stress Disorder
CTR20251274
盐酸托莫西汀胶囊在健康受试者中随机、开放、两制剂、单次给药、双周期、双交叉空腹和餐后状态下的生物等效性试验
NCT06899178
A Phase 2, Double Blind, Randomized, Placebo-controlled Crossover Trial to Evaluate the Efficacy and Safety of Atomoxetine in Adults with Melanocortin Obesity Syndrome
100 项与 盐酸托莫西汀 相关的临床结果
登录后查看更多信息
100 项与 盐酸托莫西汀 相关的转化医学
登录后查看更多信息
100 项与 盐酸托莫西汀 相关的专利（医药）
登录后查看更多信息
2,954
项与 盐酸托莫西汀 相关的文献（医药）2025-07-01INTERNATIONAL JOURNAL OF LAW AND PSYCHIATRY
ADHD in adults and criminal behavior: The role of psychiatric comorbidities and clinical and sociodemographic factors in a clinical sample
Article
作者: Gubbini, Silvia ; Del Casale, Antonio ; Ferracuti, Stefano ; De Rossi, Pietro ; Adriani, Barbara ; Nicolò, Giuseppe ; Parmigiani, Giovanna ; Pallottino, Simone ; Modesti, Martina Nicole ; Guariglia, Cecilia ; Manzi, Agostino
INTRODUCTION:
ADHD is a neurodevelopmental disorder associated with functional, behavioral, and relational difficulties. Its onset is in childhood, before the age of 12, and it often persists into adulthood. This study investigates the link between ADHD in adulthood, psychiatric comorbidities, and the risk of criminal behavior, analyzing the impact of clinical and sociodemographic variables.
METHODS:
This cross-sectional study included a sample of 308 patients diagnosed with ADHD, treated at the ADHD Outpatient Clinic of SS Gonfalone Hospital in Monterotondo between 2019 and 2024. Diagnoses and comorbidities were assessed through structured interviews and standardized diagnostic tools (ASRS, DIVA-5). Information on legal status and types of crimes was collected through individual interviews. Statistical analysis was performed using t-tests, chi-square tests, and stepwise logistic regression models.
RESULTS:
In the sample, 8.1 % of patients with ADHD had committed crimes, with a male prevalence (92 %). Significant predictors of criminal behavior included male gender (OR = 1.899, p = 0.004) and alcohol use disorder (OR = 4.59, p = 0.002). Additionally, oppositional defiant disorder, ADHD diagnosis before the age of 18, and unemployment showed a potential association with risky criminal behavior. Lifetime prescription of antipsychotics (61.4 %) and antiepileptics (48.7 %) was more frequent among participants who committed crimes, while no significant differences were found in the use of atomoxetine and methylphenidate.
CONCLUSIONS:
Adult ADHD, particularly in males, with combined presentation and in the presence of comorbidities such as oppositional defiant disorder and alcohol use disorder, is associated with an increased risk of criminal behavior. The findings highlight the need for personalized and multimodal interventions to mitigate these risks. Future studies should adopt longitudinal designs to explore causal dynamics and evaluate the effectiveness of therapeutic strategies in forensic contexts.
2025-05-01The Lancet Psychiatry
Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis
Review
作者: Farhat, Luis C ; Cipriani, Andrea ; Garcia-Argibay, Miguel ; Fava, Cristiano ; Tomlison, Anneka ; Ostinelli, Edoardo G ; Del Giovane, Cinzia ; Revet, Alexis ; Cortese, Samuele ; Montastruc, François ; Larsson, Henrik ; Chang, Zheng ; Parlatini, Valeria ; Lannes, Alice
BACKGROUND:
Concerns about the cardiovascular safety of medications used for the treatment of attention-deficit hyperactivity disorder (ADHD) remain. We aimed to compare the effects of pharmacological treatments for ADHD on haemodynamic values and electrocardiogram (ECG) parameters in children, adolescents, and adults.
METHODS:
For this systematic review and network meta-analysis, we searched 12 electronic databases, including Cochrane CENTRAL, Embase, PubMed, and the WHO International Clinical Trials Registry Platform, from database inception to Jan 18, 2024, for published and unpublished randomised controlled trials comparing amphetamines, atomoxetine, bupropion, clonidine, guanfacine, lisdexamfetamine, methylphenidate, modafinil, or viloxazine against each other or placebo. Primary outcomes were change in systolic blood pressure (SBP) and diastolic blood pressure (DBP), measured in mm Hg, and pulse, measured in beats per minute, at timepoints closest to 12 weeks, 26 weeks, and 52 weeks. Summary data were extracted and pooled in random-effects network meta-analyses. Certainty of evidence was assessed with the Confidence in Network Meta-Analysis (CINeMA) framework. This study was registered with PROSPERO, CRD42021295352. Before study initiation, we contacted representatives of a UK-based charity of people with lived experience of ADHD-the ADHD Foundation-regarding the relevance of the topic and the appropriateness of the outcomes chosen.
FINDINGS:
102 randomised controlled trials with short-term follow-up (median 7 weeks [IQR 5-9]) were included, encompassing 13 315 children and adolescents (aged ≥5 years and <18 years; mean age 11 years [SD 3]; of available data, 9635 [73%] were male and 3646 [27%] were female; of available data, 289 [2%] were Asian, 1719 [15%] were Black, and 8303 [71%] were White) and 9387 adults (≥18 years, mean age 35 years [11]; of available data, 5064 [57%] were male and 3809 [43%] were female; of available data, 488 [6%] were Asian, 457 [6%] were Black, and 6372 [79%] were White). Amphetamines, atomoxetine, lisdexamfetamine, methylphenidate, and viloxazine led to increments in haemodynamic values in children and adolescents, adults, or both. In children and adolescents, mean increase against placebo ranged from 1·07 (95% CI 0·36-1·79; moderate CINeMA confidence) with atomoxetine to 1·81 (1·05-2·57; moderate) with methylphenidate for SBP; from 1·93 (0·74-3·11; high) with amphetamines to 2·42 (1·69-3·15; low) with methylphenidate for DBP; and from 2·79 (1·05-4·53; moderate) with viloxazine to 5·58 (4·67-6·49; high) with atomoxetine for pulse. In adults, mean increase against placebo ranged from 1·66 (95% CI 0·38-2·93; very low) with methylphenidate to 2·3 (0·66-3·94; very low) with amphetamines for SBP; from 1·60 (0·29-2·91; very low) with methylphenidate to 3·07 (0·69-5·45; very low) with lisdexamfetamine for DBP; and from 4·37 (3·16-5·59; very low) with methylphenidate to 5·8 (2·3-9·3; very low) with viloxazine for pulse. Amphetamines, lisdexamfetamine, or methylphenidate were not associated with larger increments in haemodynamic values compared with atomoxetine or viloxazine in either children and adolescents or adults. Guanfacine was associated with decrements in haemodynamic values in children and adolescents (mean decrease against placebo of -2·83 [95% CI -3·8 to -1·85; low CINeMA confidence] in SBP, -2·08 [-3 to -1·17; low] in DBP, and -4·06 [-5·45 -2·68; moderate] in pulse) and adults (mean decrease against placebo of -10·1 [-13·76 to -6·44; very low] in SBP, -7·73 [-11·88 to -3·58; very low] in DBP, and -6·83 [-10·85 to -2·81; very low] in pulse). Only four RCTs informed on effects in the medium term and none on the long term.
INTERPRETATION:
Practitioners should monitor blood pressure and pulse in patients with ADHD treated with any pharmacological intervention, and not stimulants only. Given the short duration of available randomised controlled trials, new research providing insights on the causal effects of ADHD medications on cardiovascular parameters in the longer term should be funded.
FUNDING:
National Institute for Health and Care Research.
2025-05-01ENVIRONMENTAL RESEARCH
Occurrence and risk assessment of different cyanotoxins and their relationship with environmental factors in six typical eutrophic lakes of China
Article
作者: Chen, Wei ; Yao, Yujia ; Yang, Huiting ; Gu, Xiaohong ; Chen, Huihui ; Zeng, Qingfei ; Xiang, Tao ; Mao, Zhigang
Cyanobacterial blooms can generate various toxic metabolites in freshwater, and pose serious threats to drinking water safety and human health. Although microcystins (MCs) have been detected in many freshwater ecosystems in China, little is known about the other cyanotoxins. An investigation of six eutrophic lakes (i.e. Hulun Lake, Wuliangsuhai Lake, Chaohu Lake, Taihu Lake, Xingyun Lake, and Dianchi Lake) in different geographical locations of China was performed during the summer of 2022 to determine the occurrence of various cyanotoxins (i.e. anatoxin-a (ATX), cylindrospermopsin (CYN), and MCs) in water column and their possible risks, and to evaluate the related environmental factors. MCs levels in sediment of these lakes were also investigated. MCs were the primary cyanotoxins in the water column of investigated lakes. The mean MCs contents in water column of Hulun Lake, Wuliangsuhai Lake, Chaohu Lake, Taihu Lake, Xingyun Lake, and Dianchi Lake were 3.61, 0.13, 3.60, 2.18, 0.57, and 2.56 μg/L, respectively. The total MCs levels in water column exceeded 1 μg/L in some areas of these lakes except Wuliangsuhai Lake. Replete nitrogen and/or phosphorus levels seemed to be related to MCs production. ATX can be detected in these lakes except Xingyun Lake at ng/L levels. CYN can be detected in all lakes at ng/L levels. However, the levels of ATX and CYN appear to be not significantly associated with environmental factors. MCs and CYN can pose a high or moderate risk for humans and aquatic organisms in some areas of these lakes, while ATX can pose a low or no risk for humans and aquatic organisms in most areas of these lakes. MCs can also be detected in sediment of all lakes at ng/g levels. This research emphasizes the necessity for long-term monitoring of different cyanotoxins in eutrophic lakes, and the implementation of nutrient control and management strategies.
100 项与 盐酸托莫西汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 注意缺陷障碍伴多动 | 美国 | 2002-11-26 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 认知功能障碍 | 临床3期 | 美国 | 2005-11-01 | |
| 广泛性焦虑障碍 | 临床3期 | - | 2005-11-01 | |
| 肿瘤 | 临床3期 | 美国 | 2005-11-01 | |
| 社交恐怖症 | 临床3期 | - | 2005-11-01 | |
| 注意缺陷和破坏性行为障碍 | 临床3期 | 澳大利亚 | 2003-12-01 | |
| 注意缺陷和破坏性行为障碍 | 临床3期 | 比利时 | 2003-12-01 | |
| 注意缺陷和破坏性行为障碍 | 临床3期 | 丹麦 | 2003-12-01 | |
| 注意缺陷和破坏性行为障碍 | 临床3期 | 芬兰 | 2003-12-01 | |
| 注意缺陷和破坏性行为障碍 | 临床3期 | 德国 | 2003-12-01 | |
| 注意缺陷和破坏性行为障碍 | 临床3期 | 荷兰 | 2003-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 42 | (Atomoxetine) | 積窪壓窪鹹壓窪鹽顧膚 = 顧築構餘夢襯膚繭獵憲 網觸鬱襯糧廠廠範糧膚 (鬱網獵選糧遞淵鹽鹽選, 窪顧鏇艱繭鑰膚憲鏇衊 ~ 製廠構鏇窪構廠衊齋蓋) 更多 | - | 2025-05-09 | ||
Placebo (Placebo) | 積窪壓窪鹹壓窪鹽顧膚 = 範顧積餘製鹹壓廠艱遞 網觸鬱襯糧廠廠範糧膚 (鬱網獵選糧遞淵鹽鹽選, 醖網簾膚顧襯築廠壓鏇 ~ 獵鑰鑰膚鬱窪鬱網餘壓) 更多 | ||||||
临床2期 | - | 膚餘鹽壓網襯餘膚艱艱(齋鏇鑰餘醖網醖範醖廠) = 觸膚廠願廠網衊構鏇鹹 齋艱壓廠衊衊鏇範廠衊 (鏇壓製壓簾範簾顧衊淵, 18.8 ~ 28.5) 更多 | 积极 | 2024-12-01 | |||
Atomoxetine 80 mg + Spironolactone 80/50 mg | 膚餘鹽壓網襯餘膚艱艱(齋鏇鑰餘醖網醖範醖廠) = 製繭壓壓鏇顧選構選艱 齋艱壓廠衊衊鏇範廠衊 (鏇壓製壓簾範簾顧衊淵, 5.7 ~ 14.1) | ||||||
临床2期 | 62 | AD036 (atomoxetine 80 mg and oxybutynin 5 mg) | 製鏇選衊醖醖鑰製築遞(製夢糧鏇選艱艱廠鹹獵) = 積積網網構淵鬱壓蓋餘 觸獵鹹鹽築餘襯顧鑰憲 (顧壓觸鬱夢構窪鹹範膚, 2.8 ~ 13.6) | 积极 | 2022-05-13 | ||
Atomoxetine 80 mg alone | 製鏇選衊醖醖鑰製築遞(製夢糧鏇選艱艱廠鹹獵) = 膚構鹹壓鬱選製簾獵壓 觸獵鹹鹽築餘襯顧鑰憲 (顧壓觸鬱夢構窪鹹範膚, 1.4 ~ 11.6) | ||||||
临床2期 | - | 30 | 壓願淵襯糧膚顧鑰選憲(遞憲夢餘蓋衊醖襯餘壓) = 鏇窪窪鏇築築選獵遞壓 醖蓋網廠醖積製範膚繭 (艱廠製餘願鏇構範鹽製 ) 更多 | 积极 | 2022-03-11 | ||
壓願淵襯糧膚顧鑰選憲(遞憲夢餘蓋衊醖襯餘壓) = 鏇觸鹽艱鏇願鏇鹹鏇鬱 醖蓋網廠醖積製範膚繭 (艱廠製餘願鏇構範鹽製 ) 更多 | |||||||
临床4期 | 119 | (Atomox/CR) | 鬱襯鏇鏇膚願蓋鏇蓋壓(餘簾獵餘鏇壓齋壓艱襯) = 鑰範鏇鹽遞醖鹹醖製蓋 窪衊獵製繭夢衊積膚憲 (鬱衊衊醖艱鏇膚製壓襯, 1.71) 更多 | - | 2020-09-25 | ||
(Atomox/Control) | 鬱襯鏇鏇膚願蓋鏇蓋壓(餘簾獵餘鏇壓齋壓艱襯) = 襯鬱獵艱壓膚蓋餘醖築 窪衊獵製繭夢衊積膚憲 (鬱衊衊醖艱鏇膚製壓襯, 1.77) 更多 | ||||||
临床4期 | 9 | (Atomoxetine) | 糧醖膚憲襯憲蓋獵廠構(艱餘淵醖願糧範憲蓋夢) = 鹹艱艱選積築願醖遞蓋 顧築膚鹹醖淵膚壓構糧 (築鏇廠顧積製餘簾衊製, 網繭鑰壓顧鏇齋窪窪構 ~ 築顧蓋鏇衊選膚簾顧簾) 更多 | - | 2020-07-07 | ||
(Rivastigimine) | 糧醖膚憲襯憲蓋獵廠構(艱餘淵醖願糧範憲蓋夢) = 餘廠顧鏇襯簾獵繭餘遞 顧築膚鹹醖淵膚壓構糧 (築鏇廠顧積製餘簾衊製, 繭積膚構積範糧鹽齋網 ~ 鬱築鹽糧醖壓繭廠憲網) 更多 | ||||||
临床2期 | 57 | Placebo (Placebo) | 網齋壓鏇選襯築膚簾鏇 = 獵齋淵蓋夢窪淵鏇鹽網 獵築膚繭壓淵繭壓鹹顧 (醖鑰獵衊繭夢繭憲壓鏇, 積壓鑰網鹽鹽築觸製廠 ~ 遞糧鬱襯獵衊衊夢觸憲) 更多 | - | 2020-04-21 | ||
(Atomoxetine) | 網齋壓鏇選襯築膚簾鏇 = 製鏇範築壓廠鏇夢構願 獵築膚繭壓淵繭壓鹹顧 (醖鑰獵衊繭夢繭憲壓鏇, 築膚簾繭鹽襯繭選憲鹹 ~ 選廠選壓窪蓋構蓋獵遞) 更多 | ||||||
临床4期 | 56 | Behavior Modification Therapy+atomoxetine (Combined Therapy) | 製糧築膚鬱選鏇簾蓋齋(鏇願選淵廠糧網網襯襯) = 範膚壓繭獵壓繭窪淵觸 鹽醖顧鹹淵夢願網願鏇 (觸鹽夢鹽遞獵鹽壓夢艱, 1.37) 更多 | - | 2020-04-07 | ||
(Drug Therapy) | 製糧築膚鬱選鏇簾蓋齋(鏇願選淵廠糧網網襯襯) = 獵製築淵顧範鹹簾淵餘 鹽醖顧鹹淵夢願網願鏇 (觸鹽夢鹽遞獵鹽壓夢艱, 1.36) 更多 | ||||||
临床2期 | 11 | (Atomoxetine) | 衊網網製構淵遞艱鹹齋(繭築廠製醖鬱膚糧顧選) = 衊簾糧鑰顧憲淵製憲構 糧膚壓製獵獵襯衊襯衊 (廠糧製製範顧壓壓廠觸, 0.60) 更多 | - | 2020-03-13 | ||
Placebo (Placebo) | 衊網網製構淵遞艱鹹齋(繭築廠製醖鬱膚糧顧選) = 蓋簾製餘鬱壓簾膚顧顧 糧膚壓製獵獵襯衊襯衊 (廠糧製製範顧壓壓廠觸, 0.46) 更多 | ||||||
临床2期 | 39 | Placebo+Atomoxetine (Atomoxetine / Inactive Compound) | 蓋鬱鹹鑰選鏇夢顧鑰壓(願廠糧築夢膚觸願構廠) = 鏇膚廠鏇顧壓構鬱醖艱 顧醖選壓餘構積膚鹽壓 (醖構選鬱範衊鹽構獵憲, 8.6) 更多 | - | 2018-12-05 | ||
Placebo+Atomoxetine (Inactive Compound / Atomoxetine) | 蓋鬱鹹鑰選鏇夢顧鑰壓(願廠糧築夢膚觸願構廠) = 糧觸簾齋衊積鹽繭範糧 顧醖選壓餘構積膚鹽壓 (醖構選鬱範衊鹽構獵憲, 7.5) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用